Local myotoxicity from sustained release of bupivacaine from microparticles.
BACKGROUND
Sustained release of local anesthetics is frequently associated with myotoxicity. The authors investigated the role of particulate delivery systems and of the pattern of drug release in causing myotoxicity.


METHODS
Rats were given sciatic nerve blocks with bupivacaine solutions, two types of bupivacaine-containing microparticles (polymeric microspheres and lipid-protein-sugar particles), or blank particles with or without bupivacaine in the carrier fluid. Myotoxicity was scored in histologic sections of the injection sites. Bupivacaine release kinetics from the particles were measured. Myotoxicity of a range of bupivacaine concentrations from exposures up to 3 weeks was assessed in C2C12 myotubes, with or without microparticles.


RESULTS
Both types of bupivacaine-loaded microparticles, but not blank particles, were associated with myotoxicity. Whereas 0.5% bupivacaine solution caused little myotoxicity, a concentration of bupivacaine that mimicked the amount of bupivacaine released initially from particles caused myotoxicity. Local anesthetics showed both concentration and time-dependent myotoxicity in C2C12s. Importantly, even very low concentrations that were nontoxic over brief exposures became highly toxic after days or weeks of exposure. The presence of particles did not increase bupivacaine myotoxicity in vitro but did in vivo. Findings applied to both particle types.


CONCLUSIONS
Whereas the release vehicles themselves were not myotoxic, both burst and extended release of bupivacaine were. A possible implication of the latter finding is that myotoxicity is an inevitable concomitant of sustained release of local anesthetics. Particles, and perhaps other vehicles, may enhance local toxicity through indirect mechanisms.
Padera
Robert
R
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Bellas
Evangelia
E
Tse
Julie Y
JY
Hao
Daphne
D
Kohane
Daniel S
DS
D000779:Anesthetics, Local / Q000737:chemistry; D000818:Animals; D002045:Bupivacaine / Q000737:chemistry*; D002478:Cells, Cultured; D003692:Delayed-Action Preparations / Q000737:chemistry*; D008297:Male; D051379:Mice; D009183:Mycotoxins / Q000302:isolation & purification*; D032446:Myoblasts / Q000187:drug effects; D009407:Nerve Block / Q000379:methods*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000187:drug effects / Q000473:pathology*
D000779:Anesthetics, Local; D003692:Delayed-Action Preparations; D009183:Mycotoxins; D002045:Bupivacaine